Forbion, the Netherlands-based life sciences investor, raised €2.3 billion for two new venture funds, the firm’s largest fundraising to date. The capital is expected to back roughly 30 companies across the two vehicles. The announcement lands amid softer VC fundraising conditions across Europe, signaling that some managers still see opportunities in select biotech segments. For startups, larger funds can translate into more follow-on capacity and a wider pool of strategic partners. The structure of Forbion’s new vehicles may also influence how European biotechs plan runway and development timelines when competing with U.S. and China capital flows.